原发性双侧大结节性肾上腺皮质增生单侧肾上腺切除术的长期结局
这项回顾性多中心研究比较了单侧与双侧肾上腺切除术治疗PBMAH的长期结局,并与单侧肾上腺切除术治疗CPA进行对比。结果显示单侧肾上腺切除术后仅32%患者生化控制,且15%死亡(均见于未生化控制者),提示单侧手术生化控制不足可能增加死亡率。
要点
- PBMAH单侧肾上腺切除术后仅32%患者长期生化控制。
- 单侧切除组15%死亡,均见于未生化控制者。
- 单侧切除组12%需行对侧肾上腺切除。
核心结论
- PBMAH患者单侧肾上腺切除可致临床缓解和较低肾上腺危象发生率,但生化控制不足,可能增加死亡率。
研究设计与样本
- 回顾性观察性研究,在德国三家及意大利一家学术三级中心进行。
主要发现
- 术后即刻,84%的PBMAH单侧切除患者获得库欣综合征初始缓解。
- 末次随访(中位50个月)时,32%的PBMAH单侧切除患者生化控制,而其他两组几乎全部控制(P=0.000)。
- 12%的PBMAH单侧切除患者需行对侧肾上腺切除。
- PBMAH单侧切除组20例中3例(15%)死亡,推测与库欣综合征相关,其他两组无死亡(P=0.008);死亡仅见于单侧肾上腺切除后未生化控制者。
临床怎么用
- PBMAH患者选择单侧肾上腺切除时,应密切监测生化控制情况,必要时及时行对侧切除。
局限性
- 回顾性研究设计,样本量较小,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Unilateral adrenalectomy has been proposed in selected patients with primary bilateral macronodular adrenocortical hyperplasia (PBMAH), but its long-term outcome is unclear. OBJECTIVE: The aim of this study was to analyze long-term clinical and biochemical outcomes of unilateral adrenalectomy vs bilateral adrenalectomy in patients with PBMAH in comparison with the outcome of cortisol-producing adenoma (CPA) treated with unilateral adrenalectomy. DESIGN: Retrospective observational study in three German and one Italian academic tertiary care center. PATIENTS AND METHODS: Twenty-five patients with PBMAH after unilateral adrenalectomy (unilat-ADX-PBMAH), nine patients with PBMAH and bilateral adrenalectomy (bilat-ADX-PBMAH), and 39 patients with CPA and unilateral adrenalectomy (unilat-ADX-CPA) were included. RESULTS: Baseline clinical and biochemical parameters were comparable in patients with unilat-ADX-PBMAH, bilat-ADX-PBMAH, and unilat-ADX-CPA. Directly after surgery, 84% of the patients with unilat-ADX-PBMAH experienced initial remission of Cushing syndrome (CS). In contrast, at last follow-up (median, 50 months), 32% of the patients with unilat-ADX-PBMAH were biochemically controlled compared with nearly all patients in the other two groups (P = 0.000). Adrenalectomy of the contralateral side had to be performed in 12% of the initial patients with unilat-ADX-PBMAH. Three of 20 patients with unilat-ADX-PBMAH (15%) died during follow-up, presumably of CS-related causes; no deaths occurred in the other two groups (P = 0.008). Deaths occurred exclusively in patients who were not biochemically controlled after unilateral ADX. CONCLUSIONS: Our data suggest that unilateral adrenalectomy of patients with PBMAH leads to clinical remission and a lower incidence of adrenal crisis but in less sufficient biochemical control of hypercortisolism, potentially leading to higher mortality.
引用
- Osswald A, Quinkler M, Di Dalmazi G, et al. Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. J Clin Endocrinol Metab. 2019. PMID: 30844071. doi:10.1210/jc.2018-02204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。